CATEGORY

e-Consent

Electronic patient forms expected to disrupt the paper based forms market.

Beroe LiVE.Ai™

AI-powered self-service platform for all your sourcing decision needs across 1,600+ categories llike e-Consent.

Market Data, Sourcing & Supplier Intelligence, and Price & Cost Benchmarking.

Schedule a Demo
Meet Abi

The World’s first Digital Market Analyst

    Schedule a Demo
    Meet Abi

    The World’s first Digital Market Analyst

    Abi, the AI-powered digital assistant brings together data, insights, and intelligence for faster answers to sourcing questions

    e-Consent Suppliers

    e-Consent Supplier

    Find the right-fit e-consent supplier for your specific business needs and filter by location, industry, category, revenue, certifications, and more on Beroe LiVE.Ai™.

    Sample Supplier
    Company
    IQVIA HOLDINGS INC.
    Location
    Jackson, Mississipi
    Duns number
    3862211
    D&B SER Rating
    dnb logo

    Up to 3 months

    1 9
    4
    Low Risk High Risk

    The Supplier Evaluation Risk (SER) Rating is Dun & Bradstreet’s proprietary scoring system used to assess the probability that a business will seek relief from creditors or cease operations within the next 12 months. SER ratings range from 1 to 9, with 9 indicating the highest risk of failure. We’ve prepared an infographic to help business owners better understand what influences their SER Rating.

    Moody`s ESG Solution
    ESG Profile
    Company and Sector Performance
    36
    100
    Limited (1)
    ESG Perfomance (/100)
    Environment
    41
    Social
    30
    Governance
    43
    6 Domains Performance (/100)
    Business behaviour
    48
    Human rights
    39
    Community Environment
    31
    Corporate governance
    40
    Human resources
    22
    Security Scorecard
    77
    Threat indicators
    C
    75
    Network Security
    Detecting insecure network settings
    A
    100
    Hacker Chatter
    Monitoring hacker sites for chatter about your company
    D
    63
    DNS Health
    Detecting DNS insecure configuration and vulnerabilities
    C
    70
    Application Security
    Detecting common website application vulnerbilities
    C
    77
    Endpoint Security
    Detecting unprotected enpoints or entry points of user tools, such as desktops, laptops mobile devices, and virtual desktops
    A
    100
    Cubic Score
    Proprietary algorithms checking for implementation of common security best practices
    D
    60
    Patching Cadence
    Out of date company assets which may contain vulnerabilities of risk
    A
    100
    Social Engineering
    Measuring company awareness to a social engineering or phising attack
    A
    100
    IP Reputation
    Detecting suspecious activity, such as malware or spam, within your company network
    A
    100
    Information Leak
    Potentially confidential company information which may have been inadvertently leaked
    Industry Comparison
    iqvia.com
    Industry average
    Adverse Media Appearances
    Environmental Issues
    0
    Workforce Health Safety Issues
    0
    Product Service Issues
    1
    Human Rights Issues
    0
    Production Supply Chain Issues
    0
    Environmental Non Compliance Flags
    1
    Corruption Issues
    0
    Regulatory Non Compliance Flags
    2
    Fraud Issues
    0
    Labor Health Safety Flags
    0
    Regulatory Issues
    2
    Workforce Disputes
    0
    Sanctions
    0
    esg energy transition
    28
    Discrimination Workforce Rights Issues
    0
    esg controversies critical severity
    No

    e-Consent market report transcript

    Global Market Outlook on e-Consent

    Although historically there has been challenges in adopting to e-Consent platform, currently there is shift in the industry. Most of the top 10 Pharma have incorporated in almost 60 percent of their trials. Buyers who were adopting at a rate of 10-11 percent last year are turning to a higher percent of adoption, close to 21-23 percent now.

    e-consent

    Suppliers are collaborating with technology providers and amongst themselves to promote site and patient acceptance to e-Consent. Existing and new suppliers are broadening their scope of their service to align themselves to the industry shift and demand.

    • 66% of top 50 pharma are engaged or are planning to adopt to an e-Consent initiative in the near future. Most of the top 10 pharma already have an e-Consent strategy in place.
    • It is expected that, there will be a big difference when it comes to the shift in technology in the next 12 months. However, three years from now, more than 50% of the clinical trials will be adapting to e-Consent
    • Users feel the major value derived out of design and development functionalities is the use of smart devices followed by the easy content creation. This is mainly because the ability of developing a solution without vendor involvement has always been an area of worry for the stakeholders
    • Virtual care is increasingly becoming a common area of interest, as it opens a world full of possibilities for exchange of patient information.It also helps provide timely entry of any e-Informed Consent data and also for collecting subject's consent from remote locations

    Factors Impacting the Market

    • Several barriers that constrain the shift to an e-ICF mode from paper can be managed effectively, by understanding the adoption hurdles and by anticipating how the market is growing in future.
    • With the advent of virtual trials and BYOD in clinical trials, remote consent is emerging as an important topic. Patients want to use information in the comfort zone, taking the time to think and discuss with their family.